Evidence map›Paper›PMID 42720126›Full record

ReviewPediatric transplantation2026

The IPTA Nashville Consensus Conference on Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation in Children: Updates on Classification and Prevention-2026.

Michael Green, Marian G Michaels, Thomas Gross, Upton Allen, Catherine M Bollard, Olivia Martinez, Masaki Yamada, Steven H Swerdlow

2 registry-linked trialsAbstract readConsensus StatementReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05164094 phase1 / phase2active not recruitingnot on this map

A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

TypeinterventionalSponsorModernaTX, Inc.Ran2021 to 2027Enrolled867ConditionsEpstein-Barr Virus InfectionArmsmRNA-1189, Placebo
NCT06741072 phase1recruitingnot on this map

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

TypeinterventionalSponsorOhio State University Comprehensive Cancer CenterRan2026 to 2027Enrolled55ConditionsChronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant NeoplasmArmsBiospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael GreenDepartment of Pediatrics and Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-6011-2894
Marian G MichaelsDepartment of Pediatrics and Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Thomas GrossPhoenix Children's Hospital, Phoenix, Arizona, USA.
Upton AllenDivision of Infectious Diseases and the Transplant and Regenerative Medicine Center, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-2326-7731
Catherine M BollardChildren's National Hospital and the George Washington University, Washington, DC, USA.ORCID https://orcid.org/0000-0001-5140-9090
Olivia MartinezDepartment of Surgery and Program in Immunology, Stanford University School of Medicine, Stanford, California, USA.
Masaki YamadaDivision of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3393-6943
Steven H SwerdlowDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2019 International Pediatric Transplant Association (IPTA) consensus conference assessed available evidence and developed recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation in children. Because of the key role Epstein-Barr Virus (EBV) plays in the pathogenesis of many PTLD cases, it was addressed in many recommendations from the Consensus Conference. Working groups addressed and published three separate manuscripts providing recommendations and identifying key knowledge gaps relating to the diagnosis, prevention, and management of PTLD and EBV infection in this setting. The definition and classification of PTLD were actively discussed, but recommendations were not addressed in these publications. In 2025, a working group of experts in EBV and PTLD initiated an effort to review, describe, and consider the impact of newer data published since the consensus conference on the appropriateness of recommendations made and the status of knowledge gaps identified through the 2019 consensus conference's efforts. This manuscript addresses the results of this work relating to the classification and prevention of PTLD and EBV in pediatric SOT. Trial Registration: ClinicalTrials.gov identifier: NCT05164094; ID NCT06741072.

Indexed as

Lymphoproliferative DisordersOrgan TransplantationPostoperative ComplicationsChildEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumans

Identifiers

PMID42720126
PMCPMC13560100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.